Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT05479045 | A Combination Therapy Strategy to Prevent Anti-PD-1 Therapy Resistance in Metastatic Ovarian Cancer Patients | PHASE2 | NOT YET_RECRUITING | 24 | — | — | Sep 1, 2026 | Nov 1, 2028 | Mar 16, 2026 | 2 | United States |
| Arm | Type | Description |
|---|---|---|
| NY-ESO-1 Peptide vaccine plus Toripalimab-tpzi | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| NY-ESO-1 Peptide vaccine | BIOLOGICAL | 300 mcg of NY-ESO-1 peptide, 100 micrograms (mcg) granulocyte-macrophage colony-stimulating factor (GM-CSF) and 1 milliliter (mL) of Montanide ISA-51 adjuvant. The first two doses will be administered subcutaneously in a 2 week interval and thereafter, remaining three doses will be administered every 3 weeks. |
| Toripalimab-tpzi | DRUG | 240 milligrams (mg), intravenously, every 3 weeks starting with the second dose of NY-ESO-1 Peptide vaccine |
Inclusion Criteria: 1. Be able and willing to provide written and signed informed consent prior to performing any protocol-related procedures, including screening evaluations. 2. Women, 18 years or older, with stage III / IV platinum-refractory Ovarian Cancer (OC) (progressed on a platinum containi...